All In Biotech

Drug Trial Radar · NCT06058039

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 422 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

422

Actual

Start

Dec 21, 2023

Primary completion

May 4, 2026

Study completion Jun 11, 2026

Sponsor

Lead sponsor
Neumora Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Conditions

  • Major Depressive Disorder

Interventions

  • NMRA-335140Drug

    Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

  • PlaceboDrug

    Placebo will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreTime frame: Baseline and up to Week 6

Locations

71 sites in 8 countries. Site status is shown where the registry gives one.

  • Neumora Investigator Site

    Cerritos, California

  • Neumora Investigator Site

    Irvine, California

  • Neumora Investigator Site

    Long Beach, California

  • Neumora Investigator Site

    San Diego, California

  • Neumora Investigator Site

    San Francisco, California

  • Neumora Investigator Site

    New Haven, Connecticut

  • Neumora Investigator Site

    Brandon, Florida

  • Neumora Investigator Site

    Hialeah, Florida

  • Neumora Investigator Site

    Hialeah, Florida

  • Neumora Investigator Site

    Jacksonville, Florida

  • Neumora Investigator Site

    Miami, Florida

  • Neumora Investigator Site

    Miami, Florida

  • Neumora Investigator site

    Miami, Florida

  • Neumora Investigator Site

    Miami Beach, Florida

  • Neumora Investigator site

    Miami Springs, Florida

  • Neumora Investigator Site

    Palm Bay, Florida

  • Neumora Investigator Site

    Pembroke Pines, Florida

  • Neumora Investigator Site

    Pompano Beach, Florida

  • Neumora Investigator Site

    Saint Augustine, Florida

  • Neumora Investigator Site

    Atlanta, Georgia

  • Neumora Investigator Site

    Decatur, Georgia

  • Neumora Investigator Site

    Savannah, Georgia

  • Neumora Investigator Site

    Springfield, Massachusetts

  • Neumora Investigator Site

    St Louis, Missouri

  • Neumora Investigator Site

    Omaha, Nebraska

  • Neumora Investigator Site

    Berlin, New Jersey

  • Neumora Investigator Site

    New York, New York

  • Neumora Investigator Site

    New York, New York

  • Neumora Investigator Site

    Staten Island, New York

  • Neumora Investigator Site

    Charlotte, North Carolina

  • Neumora Investigator Site

    Austin, Texas

  • Neumora Investigator Site

    DeSoto, Texas

  • Neumora Investigator Site

    Fort Worth, Texas

  • Neumora Investigator Site

    Plano, Texas

  • Neumora Investigator Site

    Kardzhali, Bulgaria

  • Neumora Investigator Site

    Pleven, Bulgaria

  • Neumora Investigator Site

    Targovishte, Bulgaria

  • Neumora Investigator Site #1

    Varna, Bulgaria

  • Neumora Investigator Site

    Varna, Bulgaria

  • Neumora Investigator Site

    Cherven Bryag, Pleven, Bulgaria

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.